- Home
- ANTX vs SABS Comparison
ANTX vs SABS Comparison
Compare ANTX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANTX
- SABS
- Stock Information
- Founded
- ANTX 2017
- SABS 2014
- Country
- ANTX United States
- SABS United States
- Employees
- ANTX N/A
- SABS N/A
- Industry
- ANTX Biotechnology: Pharmaceutical Preparations
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- ANTX Health Care
- SABS Health Care
- Exchange
- ANTX Nasdaq
- SABS Nasdaq
- Market Cap
- ANTX 34.4M
- SABS 31.2M
- IPO Year
- ANTX 2022
- SABS N/A
- Fundamental
- Price
- ANTX $1.10
- SABS $3.85
- Analyst Decision
- ANTX Buy
- SABS Strong Buy
- Analyst Count
- ANTX 2
- SABS 3
- Target Price
- ANTX $2.00
- SABS $9.00
- AVG Volume (30 Days)
- ANTX 96.8K
- SABS 188.0K
- Earning Date
- ANTX 11-12-2025
- SABS 11-13-2025
- Dividend Yield
- ANTX N/A
- SABS N/A
- EPS Growth
- ANTX N/A
- SABS N/A
- EPS
- ANTX N/A
- SABS N/A
- Revenue
- ANTX N/A
- SABS $114,698.00
- Revenue This Year
- ANTX N/A
- SABS N/A
- Revenue Next Year
- ANTX N/A
- SABS N/A
- P/E Ratio
- ANTX N/A
- SABS N/A
- Revenue Growth
- ANTX N/A
- SABS N/A
- 52 Week Low
- ANTX $1.00
- SABS $1.00
- 52 Week High
- ANTX $1.68
- SABS $6.60
- Technical
- Relative Strength Index (RSI)
- ANTX 36.23
- SABS 70.06
- Support Level
- ANTX $1.13
- SABS $3.00
- Resistance Level
- ANTX $1.17
- SABS $3.59
- Average True Range (ATR)
- ANTX 0.06
- SABS 0.31
- MACD
- ANTX -0.01
- SABS 0.04
- Stochastic Oscillator
- ANTX 0.00
- SABS 85.75
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.